Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients

被引:14
|
作者
Lindenmayer, JP
Adityanjee
VitalHerne, M
Bark, N
Grochowski, S
Moynihan, N
机构
[1] VET ADM MED CTR,SCHIZOPHRENIA PROGRAM,DAYTON,OH
[2] ALBERT EINSTEIN COLL MED,BRONX PSYCHIAT CTR,SCHIZOPHRENIA RES UNIT,BRONX,NY 10467
关键词
metachlorophenylpiperazine; schizophrenia; clozapine; cortisol response; treatment refractory; serotonin;
D O I
10.1016/S0006-3223(96)00296-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oral metachlorophenylpiperazine (m-CPP) as a direct-acting postsynaptic serotonergic agonist was used to study serotonergic dysfunction in treatment-refractory chronic schizophrenia based on the hypothesis that some patients may show central serotonergic hypersensitivity, Seventeen DSM-III-R chronic schizophrenic patients with a history of neuroleptic nonresponse underwent double-blind challenge with oral m-CPP (0.25 mg/kg body weight) and placebo after medication washout, m-CPP significantly elevated both prolactin and cortisol levels as compared to placebo. There was a significant relationship between change in cortisol level and change in psychopathology under m-CPP; a blunted cortisol response was associated with a decrease in total psychopatholoy, while an increase in cortisol response related to an increase in psychopathology. Similarly, decrease in severity of the activation factor and the hostility factor was associated with a smaller cortisol response in the m-CPP condition. These results point to heterogeneity in central serotonergic sensitivity within the context of different subpopulations of serotonergic receptors. (C) 1997 Society of Biological Psychiatry.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 50 条
  • [31] Underuse and Suboptimal Use of Clozapine in Treatment-Refractory Schizophrenia
    Shad, Mujeeb U.
    PSYCHIATRIC ANNALS, 2021, 51 (12) : 576 - 578
  • [32] Correlates of cannabis misuse in adolescents with treatment-refractory schizophrenia
    Thaden, EP
    Rhinewine, J
    Kranzler, HN
    Gerbino-Rosen, G
    McMeniman, M
    Dethomas, C
    Kumra, S
    BIOLOGICAL PSYCHIATRY, 2004, 55 : 127S - 127S
  • [33] Adding or switching antipsychotic medications in treatment-refractory schizophrenia
    Kreyenbuhl, Julie
    Marcus, Steven C.
    West, Joyce C.
    Wilk, Joshua
    Olfson, Mark
    PSYCHIATRIC SERVICES, 2007, 58 (07) : 983 - 990
  • [34] AN EVALUATION OF CARBAMAZEPINE (TEGRETOL) IN CHRONIC TREATMENT-REFRACTORY SCHIZOPHRENIA
    HERRERA, J
    SRAMEK, J
    COSTA, J
    HEH, C
    WERNBERG, C
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 27 (03) : 588 - 589
  • [35] High-dose olanzapine for treatment-refractory schizophrenia
    Sheitman, BB
    Lindgren, JC
    Early, J
    Sved, M
    AMERICAN JOURNAL OF PSYCHIATRY, 1997, 154 (11): : 1626 - 1626
  • [36] CLINICAL EFFICACY OF CLOZAPINE IN TREATMENT-REFRACTORY SCHIZOPHRENIA - AN OVERVIEW
    KANE, JM
    BRITISH JOURNAL OF PSYCHIATRY, 1992, 160 : 41 - 45
  • [38] Evinacumab in patients with treatment-refractory hypercholesterolemia
    Windler, Eberhard
    Nitschmann, S.
    INTERNIST, 2021, 62 (06): : 686 - 689
  • [39] Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse
    Conley, RR
    Kelly, DL
    Gale, EA
    SCHIZOPHRENIA RESEARCH, 1998, 33 (1-2) : 95 - 101
  • [40] The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine
    Dossenbach, MRK
    Beuzen, JN
    Avnon, M
    Belmaker, RH
    Elizur, A
    Mark, M
    Munitz, H
    Schneidman, M
    Shoshani, D
    Kratky, P
    Grundy, SL
    Tollefson, GD
    CLINICAL THERAPEUTICS, 2000, 22 (09) : 1021 - 1034